Apimeds Pharmaceuticals US, Inc.

NYSE:APUS

Pharmaceutical Preparations·MATAWAN, NJ

Summary Financials

Revenue

—

Adj. EBITDA

—

Net Income

-$777,694

FY 2024

EPS (Diluted)

-$0.17

FY 2024

Stock Price

$1.31

+0.8%

2026-03-09

52W Range

$0.95 – $4.03

P/E Ratio

-7.7x

Market Cap

$16.5M

Cash

$410,481

FY 2024

Total Debt

$20,000

FY 2024

Net Cash

$390,481

FY 2024

Enterprise Value

$16.1M

Debt / EBITDA

—

EV / EBITDA

—

Employees

—

Revenue

—

Adj. EBITDA

—

Net Income

-$777,694

FY 2024

EPS (Diluted)

-$0.17

FY 2024

Stock Price

$1.31

+0.8%

2026-03-09

52W Range

$0.95 – $4.03

P/E Ratio

-7.7x

Market Cap

$16.5M

Cash

$410,481

FY 2024

Total Debt

$20,000

FY 2024

Net Cash

$390,481

FY 2024

Enterprise Value

$16.1M

Debt / EBITDA

—

EV / EBITDA

—

Employees

—